Sign Out
Sitagliptin should not be used in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis (DKA).
The dose of sitagliptin should be reduced in moderate and severe renal impairment.
Severe and disabling arthralgia has been reported with dipeptidyl peptidase-4 (DPP-4) inhibitor use; onset may occur within one day to years after treatment initiation and may resolve with discontinuation of the therapy.
After bariatric surgery, closely monitor patients for signs and symptoms of pancreatitis.
Continue with Google